EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Safety, Tolerability, and Metabolic Effects of Long-Acting Cabotegravir and Rilpivirine in HIV Care: A Comprehensive Review

Martina Bottanelli iD, Antonella Castagna, Camilla Muccini iD

Viruses · 12.08.2025 · 17 (8) · 1108

DOI: 10.3390/v17081108 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 12.08.2025. Verfasst von Martina Bottanelli und 2 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, "Alessandro Manzoni" Hospital, ASST-Lecco, 23900 Lecco, Italy. Hauptthemen laut MEDLINE: Rilpivirine, HIV Infections, Anti-HIV Agents, Pyridones. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The use of long-acting cabotegravir and rilpivirine (LA CAB/RPV) is a novel approach to manage human immunodeficiency virus (HIV). This injectable regimen offers benefits such as an improved quality of life, reduced stigma and enhanced treatment satisfaction by minimising the need for daily medication adherence. This review summarises the findings of clinical trials and real-world studies on the safety, tolerability and metabolic effects of LA CAB/RPV, which are areas that have received less extensive coverage in previous reviews. Clinical trial data suggest that LA CAB/RPV is generally safe and well tolerated. The most common side effects were injection site reactions, affecting 70–97% of participants. However, these were typically mild and short lived, rarely leading to treatment discontinuation in fewer than 2–3% of cases. Systemic side effects were minimal and comparable to those observed with traditional oral antiretroviral therapy. Real-world studies corroborated these findings, reporting low discontinuation rates due to adverse events. Regarding metabolic impact, clinical trials showed minimal weight gain (an average increase of 1–2 kg over 48–96 weeks) with no significant differences or impact on lipid and glucose levels. Although real-world data are still emerging, they suggest similar trends, including a possible improvement in lipid profiles. Overall, LA CAB/RPV appears to be a safe, well-tolerated and effective treatment option, although longer-term follow-up is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RilpivirineHIV InfectionsAnti-HIV AgentsPyridonesHumansClinical Trials as TopicDiketopiperazines

Stichwörter der Autor:innen

antiretroviral therapycabotegravirlong-actingpeople with HIVrilpivirinesafetyside effectstolerability

Substanzen

RilpivirinecabotegravirAnti-HIV AgentsPyridonesDiketopiperazines

Autor:innen und Institutionen

  • Infectious Diseases Unit, "Alessandro Manzoni" Hospital, ASST-Lecco, 23900 Lecco, Italy.
  • School of Medicine, Vita-Salute San Raffaele University, 20132 Milan, Italy.
  • Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, 20127 Milan, Italy.

ORCID-Profile: Martina Bottanelli, Camilla Muccini

Zitieren

APA

Bottanelli, M., Castagna, A., & Muccini, C. (2025). Safety, Tolerability, and Metabolic Effects of Long-Acting Cabotegravir and Rilpivirine in HIV Care: A Comprehensive Review. Viruses, 17(8), 1108. https://doi.org/10.3390/v17081108

Vancouver

Bottanelli M, Castagna A, Muccini C. Safety, Tolerability, and Metabolic Effects of Long-Acting Cabotegravir and Rilpivirine in HIV Care: A Comprehensive Review. Viruses. 2025;17(8):1108. doi:10.3390/v17081108

BibTeX
@article{Bottanelli2025,
  author = {Bottanelli, Martina and Castagna, Antonella and Muccini, Camilla},
  title = {Safety, Tolerability, and Metabolic Effects of Long-Acting Cabotegravir and Rilpivirine in HIV Care: A Comprehensive Review},
  journal = {Viruses},
  year = {2025},
  volume = {17},
  number = {8},
  pages = {1108},
  doi = {10.3390/v17081108}
}
Kostenlos starten →